Sales Performance - Net sales for the three months ended June 28, 2024, increased by 7% to $99.4 million compared to $93.1 million for the same period in 2023, primarily driven by increased ICL sales of $6.3 million [60]. - Net sales for the six months ended June 28, 2024, increased by 6% to $176.4 million compared to $165.8 million for the same period in 2023, with ICL sales contributing an increase of $12.8 million [61]. - Total ICL sales for the three months ended June 28, 2024, increased by 7% with a unit increase of 3%, while the Americas region sales increased by 14% [61]. - The EMEA region sales for the three months ended June 28, 2024, increased by 10% with unit growth of 17%, primarily due to sales increases in distributor markets [61]. - Changes in foreign currency unfavorably impacted net sales by $1.4 million for the three months ended June 28, 2024, and by $2.3 million for the six months ended June 28, 2024 [61]. Profitability - Gross profit for the three months ended June 28, 2024, increased by 10.9% to $78.4 million, with a gross profit margin of 79.2% compared to 76.6% for the same period in 2023 [64]. - The gross profit margin for the six months ended June 28, 2024, increased to 79.1% compared to 77.4% for the same period in 2023 [64]. Expenses - General and administrative expenses for the three months ended June 28, 2024 increased by 30.6% to $23,641, compared to $18,097 for the same period in 2023 [65]. - Selling and marketing expenses for the three months ended June 28, 2024 decreased by 10.7% to $28,819, compared to $32,277 for the same period in 2023 [66]. - Research and development expenses for the three months ended June 28, 2024 increased by 19.6% to $14,054, compared to $11,755 for the same period in 2023 [67]. - Other net expenses for the three months ended June 28, 2024 were $(1,564), compared to $(105) for the same period in 2023, primarily due to higher foreign exchange losses [68][69]. Taxation - Income tax provision for the three months ended June 28, 2024 was $2,955, representing a 21.7% increase from $2,428 for the same period in 2023 [70]. - The effective tax rate for the six months ended June 28, 2024 was 50.3%, compared to 33.6% for the same period in 2023 [70]. Cash Flow - Cash and cash equivalents as of June 28, 2024 were $192,776, an increase of $9,738 from $183,038 as of December 29, 2023 [72]. - Net cash provided by operating activities for the six months ended June 28, 2024 was $11,267, compared to $(11,400) for the same period in 2023 [73]. - Net cash used in investing activities for the six months ended June 28, 2024 was $(4,481), compared to $20,105 for the same period in 2023 [74]. - Net cash provided by financing activities for the six months ended June 28, 2024 was $4,219, compared to $(59) for the same period in 2023 [75]. Strategic Focus - The company plans to focus on growing its ICL business and has ceased manufacturing cataract IOLs, with no plans to sell them in 2024 [63]. - The company employs a commercialization strategy aimed at sustainable profitable growth, focusing on expanding into new markets and increasing awareness of ICL procedures [55].

Exhibit 99.1 STAAR Surgical Reports Second Quarter 2024 Results Record Quarterly Net Sales of $99.0 Million; $100.4 Million in Constant Currency Raises Fiscal 2024 Net Sales and Adjusted EBITDA Outlook LAKE FOREST, CA, August 7, 2024 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the second quarter ended June 28, 2024. Second Qua ...

Financial Data and Key Metrics Changes - For Q1 2024, the company reported net sales of $77.4 million, exceeding expectations, compared to $73.5 million in the prior year quarter [78][103] - The net loss for Q1 2024 was $3.3 million or $0.07 loss per share, compared to net income of $2.7 million or $0.05 income per share in the prior year quarter [64] - Adjusted EBITDA for Q1 2024 was $5.3 million or $0.11 per share, down from $10 million or $0.20 per share in the prior year quarter [65][68] Business Line Data and Key Metrics Changes - ICL sales increased by 9% in the Asia Pacific region, with 10% growth specifically in China [101] - The U.S. achieved record quarterly ICL sales of $5 million, representing a 21% sequential sales growth [80] - The EMEA region saw 11% sales growth, driven by the Middle East and European distributor markets [85] Market Data and Key Metrics Changes - The company anticipates net sales of approximately $95 million for Q2 2024, reflecting above-market growth rates globally [69] - In China, the market was relatively flat to down in Q1, but the company continues to gain market share, with a 10% growth expectation [20][21] - The overall market for laser vision correction was down 19% in Q1, while EVO ICL grew by 15% year-over-year [54] Company Strategy and Development Direction - The company is focusing on the Highway 93 initiative, which is yielding positive results and is expected to be applied globally [6][42] - A second distributor has been added in China to enhance efficiency and market penetration, particularly in Tier 3 and Tier 4 cities [26][111] - The company aims to increase surgeon confidence and expand its market share through strategic investments and partnerships [88][120] Management Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the macroeconomic environment, noting a choppy economic landscape in China but positive signs of recovery [56][57] - The company is committed to maintaining a strong presence in China, with plans to increase the workforce from 80 to over 100 employees [25][102] - Management highlighted the importance of surgeon confidence and the positive impact of recent clinical data on the adoption of EVO ICL [97][100] Other Important Information - The company has reached a record level of cash on its balance sheet, totaling $252.1 million at the end of Q1 2024 [58] - Total operating expenses for Q1 2024 were $63.3 million, up from $54.8 million in the prior year quarter [91] - The company is investing in new hires and initiatives to drive future growth and market expansion [87][112] Q&A Session Summary Question: Can you provide insights on the U.S. initiatives and their performance? - Management noted that the U.S. results exceeded expectations, with a focus on the Highway 93 initiative and new partnerships driving growth [51][62] Question: What are the expectations for growth in China and the impact of stimulus? - Management indicated that stimulus measures are being well received, and they expect growth in the second half of the year [16][27] Question: How is the company addressing competition in the market? - Management acknowledged the presence of competition but expressed confidence in their strategies and market position [14][125] Question: Can you elaborate on the performance of Highway 93 accounts? - Management reported strong performance from Highway 93 accounts, with a significant increase in ICL procedures [130] Question: What are the expectations for gross margin and operating expenses? - Management expects gross margin to remain around 80% of net sales and operating expenses to be consistent with prior periods [90][112]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 29, 2024 Or STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic Ocean Drive Lake Forest, California 92630 (Address of Principal Executive Of ices) (Zip Code) Delaware 95-3797439 (I.R.S. E ...

Exhibit 99.1 STAAR Surgical Reports First Quarter 2024 Results EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA LAKE FOREST, CA, May 7, 2024 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact name of registrant as specified in its charter) Delaware 95-3797439 (State or other jurisdiction o ...

STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Conference Call February 26, 2024 4:15 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Patrick Wood - Morgan Stanley John Young - Canaccord Margaret Andrew - William Blair George Sellers - Stephens Inc. Ryan Zimmerman - BTIG Anthony Petrone - Mizuho Group Matthew O'Brien - Piper Sandl ...

Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 UNITED STATES SECURITIES AND EXCHANGE COMMISSION STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlan ...

STAAR Surgical Company (NASDAQ:STAA) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Anthony Petrone - Mizuho Xuyang Li - Jefferies John Young - Canaccord George Sellers - Stephens Margaret Kaczor Andrew - William Blair Steve Lichtman - Oppenheimer Operator Good day ladies and gentle ...

STAAR Surgical Company (NASDAQ:STAA) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Brian Moore - Investor Relations Tom Frinzi - President and Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Group Margaret Kaczor - William Blair Young Li - Jefferies Samuel Durno - BTIG Harrison Parsons - Stephens Inc. Tom Stephan - Stifel David Saxon - Needham Jim Sidoti - Sidoti & Company Steve Lichtman - Oppenheimer ...